United States

People: Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

12:01pm EDT
Change (% chg)

$-0.15 (-2.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Molineaux, Susan 

Dr. Susan M. Molineaux, Ph.D. serves as President, Chief Executive Officer, Co-Founder and Director of Calithera Biosciences Inc. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix’s acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000, she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporation and Theravance Biopharma, Inc. and is a Scientific Advisor for Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.

Basic Compensation

Total Annual Compensation, USD 756,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 4,939
Fiscal Year Total, USD 760,939

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Susan Molineaux


Sumita Ray


Curtis Hecht


Christopher Molineaux


Keith Orford


Eric Sjogren

As Of  30 Dec 2017